ReviewCurrent opinion in allergy and clinical immunology2020
Childhood asthma in the new omics era: challenges and perspectives.
Review in Current opinion in allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Multi-omics integration reveals BPGM downregulation and potential plasma metabolite biomarkers for childhood asthma.Frontiers in pediatrics · 2026Article
- Review
- Integrating multi-omics data of childhood asthma using a deep association model.Fundamental research · 2024Article
- Omics approaches in asthma research: Challenges and opportunities.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Serum proteomics identifies novel diagnostic biomarkers for asthma in preschool children.Journal of thoracic disease · 2024Article
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- Differentially expressed microRNAs in peripheral blood cell are associated with downregulated expression of IgE in nonallergic childhood asthma.Scientific reports · 2023Article
- Utility of biomarkers in the diagnosis and monitoring of asthmatic children.The World Allergy Organization journal · 2023Review
- Precision diagnostics in children.Cambridge prisms. Precision medicine · 2023Review
- The Burden of Childhood Asthma by Age Group, 1990-2019: A Systematic Analysis of Global Burden of Disease 2019 Data.Frontiers in pediatrics · 2022Article
- Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy.ERJ open research · 2021Article
- Treating severe asthma: Targeting the IL-5 pathway.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2021Review
- Biologicals in childhood severe asthma: the European PERMEABLE survey on theERJ open research · 2021Article
- Breathomics in Asthmatic Children Treated with Inhaled Corticosteroids.Metabolites · 2020Article
- Childhood asthma in the new omics era: challenges and perspectives: Erratum.Current opinion in allergy and clinical immunology · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewChildhood asthma is a heterogeneous inflammatory disease comprising different phenotypes and endotypes and, particularly in its severe forms, has a large impact on the quality-of-life of patients and caregivers. The application of advanced omics technologies provides useful insights into underlying asthma endotypes and may provide potential clinical biomarkers to guide treatment and move towards a precision medicine approach. RECENT
findingsThe current article addresses how novel omics approaches have shaped our current understanding of childhood asthma and highlights recent findings from (pharmaco)genomics, epigenomics, transcriptomics, and metabolomics studies on childhood asthma and their potential clinical implications to guide treatment in severe asthmatics. SUMMARY: Until now, omics studies have largely expanded our view on asthma heterogeneity, helped understand cellular processes underlying asthma, and brought us closer towards identifying (bio)markers that will allow the prediction of treatment responsiveness and disease progression. There is a clinical need for biomarkers that will guide treatment at the individual level, particularly in the field of biologicals. The integration of multiomics data together with clinical data could be the next promising step towards development individual risk prediction models to guide treatment. However, this requires large-scale collaboration in a multidisciplinary setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.